<DOC>
	<DOCNO>NCT01276977</DOCNO>
	<brief_summary>The purpose study Compare efficacy zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet acute treatment migraine . To develop evaluate set importance weight predefined set treatment attribute migraine suffers use zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet . To contrast efficacy zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet early time point . To analyze pattern self-reported tolerability migraine sufferer use zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet .</brief_summary>
	<brief_title>Zolmitriptan Nasal Spray Versus Eletriptan Acute Treatment Migraine</brief_title>
	<detailed_description>An open-label , randomize , cross-over study compare efficacy zolmitriptan 5 mg nasal spray eletriptan 40 mg tablet early time point . Satisfaction endpoint include global assessment preference , overall satisfaction effectiveness well tolerability medication .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Headache Disorders</mesh_term>
	<mesh_term>Eletriptan</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>15 70 year old Migraine attack accord criterion propose IHS 312 Migraine attack per month adequate contraception Willing able give write informed consent Willing able complete entire course study &amp; comply instruction Stable dose preventive medication least 4 week Disorders listen group 511 IHS Classification Subject pregnant lactating . Significant medical psychiatric disease Subject history symptom suggestive ischemic heart disease ( angina , myocardial infarction , document silent ischemia ) vascular disease , include Prinzmetal angina , claudication , WolffParkinsonWhite syndrome , cardiac accessory conduction pathway arrhythmia Subject uncontrolled hypertension . Subject history basilar , ophthalmoplegic , hemiplegic migraine serious neurologic condition associate headache Subject use monoamine oxidase A inhibitor ( MAOIAs ) within 2 week randomization Subject serious adverse event use another 5HT agonist , previous serious adverse event use zolmitriptan hypersensitivity zolmitriptan eletriptan Using CYP3A4 inhibitor list FDA contraindicate eletriptan Moderate/severe hepatic/renal impairment Subject currently use cimetidine Concomitant medication treatment triptan , ergotamine methysergide .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Acute Migraine</keyword>
	<keyword>Headache</keyword>
</DOC>